Erschienen in:
01.12.2015 | Letter to the Editor
Comment on Dornoff et al.: Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck
verfasst von:
Klaus Müller, MD, MBA, Gunther Klautke, MD
Erschienen in:
Strahlentherapie und Onkologie
|
Ausgabe 12/2015
Einloggen, um Zugang zu erhalten
Excerpt
In the article “Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck” Dornoff et al. suggested a new prognostic score for the survival of relapsed head and neck cancer patients after salvage treatment consisting of re-irradiation with concurrent immuno- or chemotherapy. Ranging from 0 to 4 points, the score classified patients into five groups with excellent (4 points), good (3 points), moderate (2 points), poor (1 point), and very poor (0 points) outcome. The authors finally stated that their tool would be useful to identify suitable patients for re-irradiation [
1]. …